Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 560.00
Bid: 550.00
Ask: 566.00
Change: 10.00 (1.82%)
Spread: 16.00 (2.909%)
Open: 568.00
High: 568.00
Low: 550.00
Prev. Close: 550.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

2 Sep 2020 07:00

RNS Number : 7412X
Gooch & Housego PLC
02 September 2020
 

For immediate release

2 September 2020

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Trading Update

 

"Trading in line with expectations"

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, provides an update for the 10 months ended 31 July 2020. Overall, trading remains in line with management's expectations for the full year ending 30 September 2020.

Trading

The Group's manufacturing locations in the UK, USA and China are now fully open, thanks to measures that were quickly and efficiently put in place by our site teams, minimising the disruption of the COVID-19 pandemic for our customers whilst keeping our employees safe. Most recently, our Torquay site in the UK has returned to full capacity.

Trading levels in June and July reflected the recovery in the Company's manufacturing capacity and some of our larger customers' manufacturing sites reopening.

Orders for fibre optics, hi- reliability fibre couplers for undersea cables and our A&D and life science capabilities remain robust. There continues to be improved demand for medical diagnostics, in particular for ventilator systems. As previously communicated, industrial laser demand remains at below "normalised" levels, although the semiconductor subsector has demonstrated sustained improvement.

The previously announced cost control measures have been implemented and will support the Group's profitability in H2 FY '20 and beyond.

Priorities in the COVID-19 emergency

Our primary concern during the emergency is the health and safety of our staff, customers and suppliers. Extensive measures have been put in place at all of our sites to ensure we rigorously meet social distancing and cleanliness requirements and all other relevant guidelines and regulations.

Financial strength

The Company remains in a good financial position with a strong balance sheet and liquidity levels that have continued to improve during the period. Total headroom increased to £28.1 million; this included a $10 million extension to the Group's revolving credit facility taking the total to $50 million, as announced in April 2020.

Outlook

There remains significant global economic uncertainty due to the COVID-19 emergency in the short term. That said, our telecommunications, A&D and life sciences businesses have held up well during the period, though the timing and pace of the industrial laser market recovery remains difficult to predict.

Improved industrial laser demand will be driven by technical innovation such as 5G and new laser based manufacturing techniques. There remains substantial long term growth potential for our photonic technologies and system capabilities in all of our target sectors.

The streamlining of our manufacturing sites is on schedule and will deliver the profit improvements previously announced.

 

Mark Webster, Chief Executive Officer of Gooch and Housego, commented:

"We are proud of the way that our staff and management have responded to the COVID-19 emergency. All of our sites in the UK, USA and China are now open and fully compliant with all relevant health and safety requirements. This has been achieved, quickly, efficiently and most importantly, safely.

"While there remains considerable short term economic uncertainty our order book remains robust, the Company's balance sheet has strengthened during the period and we have continued to invest in our high priority R&D targets.

"The COVID-19 emergency has validated G&H's long term strategy of diversification and moving up the value chain. We will continue to pursue this policy through internal investment and where appropriate, acquisitions."

 

 

 

 

For further information contact: -

 

Mark Webster/Chris Jewell

Gooch & Housego PLC

01460 256440

Mark Court/ Charlotte Slater

Buchanan

020 7466 5000

Chris Baird/Patrick Robb/

David Anderson

Investec Bank plc

020 7597 5970

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSSDESFESSEFU
Date   Source Headline
29th Sep 201111:52 amRNSBoard Change
8th Jun 20117:00 amRNSInterim Results
12th May 201112:24 pmRNSNotice of Results
1st Apr 20117:00 amRNSAcquisition and Trading Update
23rd Feb 20117:00 amRNSProgress Update for Today's Annual General Meeting
28th Jan 20118:10 amRNSDirector/PDMR Shareholding
25th Jan 20118:30 amRNSAcquisition of EM4
24th Jan 201112:07 pmRNSAdditional Listing
19th Jan 201111:45 amRNSUS Regulatory Approval
13th Jan 20114:55 pmRNSNotification of Interests
13th Jan 20114:55 pmRNSDirector Shareholdings
13th Jan 20114:53 pmRNSAdditional Listing
5th Jan 20111:42 pmRNSResult of EGM
16th Dec 20102:37 pmRNSProposed Acquisition, Placing and General Meeting
2nd Dec 20108:52 amRNSDividend
30th Nov 20107:00 amRNSPreliminary Results
15th Nov 20107:00 amRNSNotice of Results
5th Oct 20107:00 amRNSFull-Year Trading Update
17th Sep 20102:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSTrading Update
8th Jun 20107:00 amRNSInterim Results
18th May 20107:00 amRNSNotice of Results
8th Apr 20107:00 amRNSHalf-Year Trading Update
26th Mar 20103:33 pmRNSHolding(s) in Company
12th Mar 20108:56 amRNSDirector/PDMR Shareholding
25th Feb 201011:00 amRNSResult of AGM
24th Feb 20107:00 amRNSProgress Update for Today's Annual General Meeting
26th Jan 20108:24 amRNSDirector/PDMR Shareholding
18th Jan 20103:48 pmRNSAward of Share Options
7th Jan 20103:09 pmRNSAward of share-based incentives
1st Dec 20097:00 amRNSPreliminary Results
12th Nov 20098:56 amRNSNotice of Results
6th Oct 20097:00 amRNSFull-Year Trading Update
23rd Jul 20097:00 amRNSAppointment of new executive director
9th Jun 20097:00 amRNSInterim Results
13th May 20098:57 amRNSNotice of Results
2nd Apr 20097:00 amRNSResult of AGM
31st Mar 20097:00 amRNSHalf-Year Trading Update
23rd Mar 20097:00 amRNSBoard Change
9th Mar 20097:00 amRNSMarket Update
29th Jan 20094:04 pmRNSTrading Update
1st Dec 200810:56 amRNSDirector Share Dealing
25th Nov 200812:27 pmRNSPreliminary Results - Replacement
25th Nov 20087:00 amRNSPreliminary Results
5th Nov 20087:00 amRNSNotice of Results
10th Oct 20087:00 amRNSAcquisition of General Optics
9th Oct 20087:00 amRNSFull Year Trading Update
25th Sep 200811:47 amRNSInvestor and Analyst Site Visits
19th Sep 20083:11 pmRNSShare Option Purchase
4th Jul 20087:00 amRNSAcquisition of General Optics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.